Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors

Hematol Oncol Clin North Am. 2016 Feb;30(1):179-91. doi: 10.1016/j.hoc.2015.09.009.

Abstract

Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.

Keywords: Carcinoid; Neuroendocrine tumor; PRRT; Radionuclide therapy; Treatment.

Publication types

  • Review

MeSH terms

  • Disease-Free Survival
  • Humans
  • Intestinal Neoplasms / diagnostic imaging
  • Intestinal Neoplasms / metabolism
  • Intestinal Neoplasms / radiotherapy*
  • Neuroendocrine Tumors / diagnostic imaging
  • Neuroendocrine Tumors / metabolism
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives
  • Octreotide / metabolism
  • Octreotide / therapeutic use*
  • Pancreatic Neoplasms / diagnostic imaging
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / radiotherapy*
  • Radioisotopes / metabolism
  • Radioisotopes / therapeutic use
  • Radionuclide Imaging
  • Radiopharmaceuticals / metabolism
  • Radiopharmaceuticals / therapeutic use*
  • Receptors, Peptide / metabolism
  • Remission Induction
  • Stomach Neoplasms / diagnostic imaging
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / radiotherapy*

Substances

  • 177Lu-octreotide, DOTA(0)-Tyr(3)-
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Peptide
  • 90Y-octreotide, DOTA-Tyr(3)-
  • Octreotide

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor